media – Page 538 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs). BPX-501 is an adjunct T cell therapy incorporating CaspaCIDe® administered after haploidentical hematopoietic stem cell transplant (haplo-HSCT) for the treatment of hematologic cancers and inherited blood diseases.
- Source: ir.bellicum
- 546
- March 19, 2018
AML BPX-501 Clinical Trials PIDs T cell therapy
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer

Erdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, shows promise as the first targeted agent for patients with metastatic urothelial cancer, one of the most common cancers
- Source: janssen
- 616
- March 19, 2018
erdafitinib FDA Janssen Johnson & Johnson
mHealth Tools, AI Combine to Avert Serious Diabetic Health Issues

mHealth tools embedded with AI technology are helping doctors and those living with diabetes detect hyperglycemia and hypoglycemia up to an hour ahead of time, averting serious and potentially fatal health issues.
- Source: drugdu
- 1,243
- March 19, 2018
AI Company Insight digital health mHealth
Preview — Global Pharmaceutical and Medical Device Exhibitions in the Second Quarter of 2018

Have you prepared for all the exhibitions you want to attend in the second quarter of 2018? Ddu, the leading global pharmaceutical & medical device B2B online platform, plans to attend a number of major international pharmaceutical and medical device exhibitions in the second quarter of this year. Here is a summary of each event:
- Source: Ddu
- 149,654
- March 16, 2018
Exhibitions & Activities medical device pharmaceutical
GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm

Investors who pressed GlaxoSmithKline to slash new CEO Emma Walmsley’s pay package before she took the helm probably won’t much like her overall compensation figure for 2017.
- Source: fiercepharma
- 553
- March 16, 2018
Company Insight GSK
Boehringer, Vanderbilt U to develop cancer MCL1 inhibitors in third team-up

Cancer cells are different from normal cells in that they can avoid a naturally programmed cell death process known as apoptosis and grow almost indefinitely. In their third collaboration, Boehringer Ingelheim and Vanderbilt University have their eyes on a target that helps cancer cells evade death.
- Source: fiercebiotech
- 445
- March 16, 2018
apoptosis Company Insight MCL1
Researchers in aging tie genes to brain degeneration

As brain cells age, they lose their ability to perform basic functions, often leading to dementia and other neurodegenerative disorders. But what’s behind this decline, and can it be stopped? Two new studies out this week uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.
- Source: fiercebiotech
- 454
- March 16, 2018
Dementia neurodegenerative Researches
New guidelines recommend hysteroscopy test for heavy periods

More women in England and Wales are to be offered a test to better determine the causes of heavy menstrual bleeding, on updated guidelines from the National Institute for Health and Care Excellence.
- Source: pharmatimes
- 392
- March 16, 2018
Hysteroscopy menstrual bleeding Researches
First step in development of pill-based vaccines

Researchers from Cardiff University have created the world’s first synthetic, non-biologic vaccine.
- Source: cardiff.ac.uk
- 489
- March 16, 2018
influenza vaccine non-biologic Researches
OWLSTONE MEDICAL RAISES $15 MILLION USD (£11 MILLION GBP) WITH HORIZONS VENTURES AND AVIVA

SBRI Healthcare alumni and Cambridge-based Owlstone Medical has announced that it has raised $15 million (£11 million) to drive the global commercialisation of its Breath Biopsy® platform.
- Source: eahsn.org
- 527
- March 16, 2018
Breath Biopsy® platform lung cancer Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.